Should I Buy CMMB? CMMB 2026 Analysis

Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.520

1 Day change

1.00%

52 Week Range

5.480

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Chemomab Therapeutics Ltd (CMMB) is not a good buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, and there are no significant positive catalysts, news, or trading signals to support an entry. Additionally, there is no financial data or valuation information available to assess the company's growth potential.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. The RSI is neutral at 30.311, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 1.534 and resistance at 1.684.

Positive Catalysts

NULL. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

Bearish technical indicators, no recent positive news, and no significant trading activity from insiders or hedge funds.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

2 Analyst Rating

Wall Street analysts forecast CMMB stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.505

Low

Averages

17.5

High

Current: 1.505

Low

Averages

17.5

High

Oppenheimer

Outperform

maintain

$10 -> $25

AI Analysis

2025-08-27

Reason

Oppenheimer

Price Target

$10 -> $25

AI Analysis

2025-08-27

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Chemomab Therapeutics to $25 from $10 and keeps an Outperform rating on the shares to reflect Q2 results and management's intent to advance nebokitug in primary sclerosing cholangitis solely based on a third-party partnership, licensing or other similar transaction. The firm, which notes that its raised target reflects the potential value it sees to shareholders under an M&A or licensing scenario, points out that it also accounts for the company's 4-to-1 reverse share split.

CMMB Should I Buy

CMMB Should I Buy

Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch